HR Execs on the Move

Janux Therapeutics

www.januxrx.com

 
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.januxrx.com
  • 10955 Vista Sorrento Parkway Suite 200
    San Diego, CA USA 92130
  • Phone: 858.751.4493

Executives

Name Title Contact Details
Brenda Van Vreeswyk
Head of Human Resources Profile
David Campbell
President and Chief Executive Officer Profile

Similar Companies

Compass Therapeutics

Compass Therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. Compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. Novel scientific insights are validated and explored deeply inside our labs before Compass pursues the best proprietary combinations of therapeutics into human clinical trials.

Cybin

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Concerro

Concerro is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Complete Testing Solutions

Complete Testing Solutions is a Gilbert, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tonix Pharmaceuticals

Tonix Pharmaceuticals develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix`s lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution ((R)-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.